Core Insights - Hutchison China MediTech Limited (HCM) announced the renewal of its medical insurance agreements with the National Healthcare Security Administration (NHSA) for several of its drugs, effective from January 1, 2026 [1][2] - The inclusion of ELUNATE® (fruquintinib), ORPATHYS® (savolitinib), and SULANDA® (surufatinib) in the updated National Medical Insurance Drug List signifies continued support for innovative cancer treatments in China [1][2] - TAZVERIK® (tazemetostat) has been added to the inaugural Commercial Health Insurance Innovative Drug List, enhancing access to advanced therapies for patients with specific conditions [1][2] Drug-Specific Summaries - ELUNATE® is approved for use in combination with the anti-PD-1 therapy, sintilimab, for treating advanced endometrial cancer patients who have failed prior systemic anti-tumor therapy and are not suitable for curative surgery or radiotherapy [1] - ELUNATE® is also renewed for treating metastatic colorectal cancer patients who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, as well as those who have received or are unsuitable for VEGF and EGFR-targeted therapies [1] - ORPATHYS® is included for treating adults with locally advanced or metastatic non-small cell lung cancer harboring MET exon 14 alterations [1][2] - SULANDA® is renewed for treating unresectable locally advanced or metastatic, progressive, non-functional, well-differentiated (G1, G2) neuroendocrine tumors of pancreatic and non-pancreatic origin [2] - TAZVERIK® is included in the Commercial Health Insurance Innovative Drug List for adult patients with EZH2 mutation-positive relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [2] Policy and Market Implications - The NHSA's announcement of the 2025 adjustment plan for the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List highlights a focus on high-innovation, clinically valuable drugs that exceed the basic insurance coverage [2] - The establishment of the Commercial Health Insurance Innovative Drug List aims to enhance patient access to breakthrough therapies and supports the sustainable development of China's innovative pharmaceutical industry [2]